• 1 January 1985
    • journal article
    • Vol. 83, 82-113
Abstract
Clinical research utilizing the yellow, orange, and red wavelengths of the dye laser (Rhodamine 6G and MD-631) appears to have considerable promise and may demonstrate that the liquid organic dye laser is the laser of choice for photocoagulation of many types of ocular defects. The effectiveness of the dye laser as a photocoagulation source is due to the trans-spectral availability of relatively high output power wavelengths. Therefore, a target tissue can be selectively coagulated with minimal laser energy transmitted through the refractive media and minimal damage to nearby normal tissues. The dye laser, as a photocoagulation system, should prove valuable in the therapy of many ocular diseases.